Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Next Previous
Trial Profile

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer; Liver cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 18 Jun 2025 Planned End Date changed from 30 Dec 2025 to 31 Dec 2025.
  • 03 Mar 2025 Planned End Date changed from 2 Dec 2024 to 30 Dec 2025.
  • 08 Jul 2024 Planned End Date changed from 2 Jun 2024 to 2 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top